Arrangement for Potelligent CHOKS1V covers research and commercial recombinant antibody production.
BioWa and Lonza have licensed their recently launched Potelligent® CHOKS1V cell line to Daiichi Sankyo for use in the development and production of recombinant therapeutic antibodies. The firms say the research and commercial licensing deal is the first for the new cell line.
The Potelligent CHOKS1V technology combines BioWa’s Potelligent engineered glycosylation platform with Lonza’s CHOK1SV cell line, developed using its GS Gene Expression System™. The Potelligent platform is designed to allow the creation of 100% fucose-free monoclonal antibodies, which BioWa claims increases Fc receptor binding, enhances antigen dependent cellular cytotoxicity, and lowers the effective therapeutic dose.
The companies maintain studies have shown Potelligent antibodies display increased cytotoxicity against low-density antigens, while exhibiting higher efficacy at lower doses than conventional mAbs. A number of Potelligent antibodies are already in clinical trials.
